|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Regarding tumor type, adrenocorticotropic hormone (ACTH), prolactin (PRL), growth hormone (GH), non-functioning and multiple-secreting adenomas accounted for 35.7%, 25.7%, 12.2%, 25.7%, and 0.7% of the tumors, respectively.
|
31376772 |
2019 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
|
30400048 |
2019 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Transsphenoidal adenenomectomy yielded an adenoma diffusely positive for prolactin.
|
30898745 |
2019 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Despite suppression of prolactin levels with cabergoline, the pituitary tumor continued to increase in size and the patient developed clinical symptoms and biochemistry consistent with the diagnosis of acromegaly due to acidophilic stem cell adenoma, an extremely rare subtype of mixed growth hormone/prolactin adenoma, which behaves more aggressively and has a lower surgical cure rate compared to the pure GH-secreting adenoma.
|
31721135 |
2019 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactin-secreting adenomas (prolactinomas) are the most common secreting adenomas of the pituitary.
|
30404098 |
2019 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis.
|
31001736 |
2019 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Radiation therapy (RT) is an effective treatment for patients with either nonfunctioning or secreting pituitary adenomas unsuccessfully treated by surgery and/or medical therapy, resulting in local control of 90-95% at 5-10 years and variable normalization of hormonal hypersecretion for patients with GH-, ACTH-, and prolactin-secreting adenomas in the range of 40-80% at 5 years; however, its use has been limited because of concerns regarding potential late toxicity of radiation and delayed efficacy in normalization of hormone hypersecretion.
|
31053487 |
2019 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Current guidelines for serum prolactin level cutoffs to distinguish between pathologies are suboptimal because they fail to consider the adenoma volume.
|
31200381 |
2019 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Remission was associated with older maternal age (P = 0.036), a lower prolactin level at diagnosis (P = 0.037), and a smaller adenoma at diagnosis (P = 0.045).
|
31583693 |
2019 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
At last assessment (median follow-up 3 years) and compared with values 6-12 months after stopping DA, Prolactin (PRL) increased in 15%, decreased but not normalized in 33% and was normal in 52%; PRL levels or visible adenoma on imaging before DA withdrawal, treatment duration and presence of macro-/microadenoma at diagnosis were not predictors of normoprolactinaemia at last review, whereas PRL values 6-12 months after stopping DA were.
|
29894000 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, there were no significant differences in postoperative remission rates among patients with prolactin adenomas from different ethnic groups (P > .05).
|
30407358 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactin-secreting adenomas, or prolactinomas, cause hypogonadism, osteoporosis, and infertility.
|
29726995 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas.
|
29399201 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Common pituitary tumours were prolactin-secreting adenomas (45%), non-functioning pituitary adenomas (NFPAs: 35.6%), growth hormone (GH)-secreting adenomas (10.6%), craniopharyngiomas (7%), and adrenocorticotropic hormone (ACTH)-secreting adenomas (1.8%).
|
29858852 |
2018 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
RESULTS ACTH, GH, TSH, PRL, FSH, and LH levels in 38 patients with pituitary null cell macroadenoma were not statistically different from the 28 patients with pituitary null cell giant adenoma; the general pituitary hormone score in the former group was significantly increased compared with the latter group (P<0.05).
|
30397189 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Histological analysis after surgery revealed adenoma with positive staining for prolactin.
|
29934876 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
|
27708194 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Histotype of atypical adenomas figured out to be nonfunctioning in 23 cases (46 %), PRL secreting in 10 cases (20 %), ACTH secreting and GH secreting each apart in 8 patients (16 %), and in a single case a GH/PRL secreting adenoma (2 %).
|
27215912 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In total, 42 reported cases were identified and included in our analysis: 23 cases of prolactin-secreting adenomas and 19 of prolactin-secreting carcinomas.
|
28742502 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We have used a previously described Hmga2/T mouse model developing haemorrhagic prolactin-secreting adenomas.
|
28152577 |
2017 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A functional pituitary adenoma can produce multiple anterior-pituitary hormones, such as growth hormone (GH) -producing adenomas (GHoma) with prolactin or thyrotropin stimulating hormone production in the same lineage.
|
28865461 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Early surgical intervention is the key, especially in the setting of pathologic features indicating aggressive tumor behavior or worsening visual function but is generally not indicated in prolactin-secreting adenomas that may respond to medical therapy.
|
28131872 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Pituitary tissue surrounding the adenomas in patients with multiple adenomas revealed hyperplastic GH- and prolactin-positive tissue.
|
27509071 |
2017 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, we found prolactinoma patients with 25-hydroxyvitamin D >20.00 ng/ml showing significant differences in the prolactin levels and adenoma size when compared with those who had 25- hydroxyvitamin D <20.00 ng/ml.
|
28595559 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
PD-L1 RNA and protein expression were significantly increased in functioning (growth hormone and prolactin-expressing) pituitary adenomas compared to non-functioning (null cell and silent gonadotroph) adenomas.
|
27655724 |
2016 |